Royalty Pharma Announces $2.85 billion Acquisition of Royalty Rights in multiple sclerosis drug Tysabri® (natalizumab) from Perrigo Company plc

Dublin, Ireland and New York, NY - February 27, 2017 – Royalty Pharma buys royalty on worldwide sales of Tysabri® (natalizumab) for $2.2 billion plus potential milestone payments of $250 million in 2018 and $400 million in 2020 to be paid if Tysabri sales exceed certain levels.

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.